Markets & Finance

On the Drug and Biotech Frontier

Guests: Herman Saftlas, Standard & Poor's investment officer, and Frank

DiLorenzo, S&P analyst

Explore the market for stocks of pharmaceutical and biotech companies with

two Standard & Poor's experts. Find out what names hold the most promise for

your portfolio, in another of the chats presented every Tuesday at the same

time by BusinessWeek Online and S&P.

Our guests are S&P investment officer Herman Saftlas. He has more than 30

years of experience tracking stocks for S&P -- and has been checking out the

pharmas for 15 years. He's a graduate of Queens College in New York City.

Analyst Frank DiLorenzo has been covering the exciting biotech area for two

years at S&P. Previously, he was a fixed-income analyst for MetLife. He holds

an MBA from Rutgers.

The moderator of this chat with Herman and Frank will be Jack Dierdorff

(JackBW), consulting editor of BusinessWeek Online and former managing editor

of the magazine. Get your questions ready!

The Aging of Abercrombie & Fitch
blog comments powered by Disqus